Replimune Group (REPL) Stock Forecast, Price Target & Predictions
REPL Stock Forecast
Replimune Group stock forecast is as follows: an average price target of $24.20 (represents a 117.43% upside from REPL’s last price of $11.13) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
REPL Price Target
The average price target for Replimune Group (REPL) is $24.20 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $43.00 to $13.00. This represents a potential 117.43% upside from REPL's last price of $11.13.
REPL Analyst Ratings
According to 6 Wall Street analysts, Replimune Group's rating consensus is 'Buy'. The analyst rating breakdown for REPL stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Replimune Group Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 07, 2024 | Robert Burns | H.C. Wainwright | $17.00 | $7.11 | 139.10% | 52.74% |
| Jun 04, 2024 | Peter Lawson | Barclays | $13.00 | $5.37 | 142.09% | 16.80% |
| May 17, 2024 | Evan Seigerman | BMO Capital | $14.00 | $6.85 | 104.38% | 25.79% |
| Dec 12, 2022 | - | BMO Capital | $70.00 | $25.00 | 180.00% | 528.93% |
| Dec 07, 2022 | - | Leerink Partners | $34.00 | $23.09 | 47.25% | 205.48% |
| Oct 03, 2022 | - | Leerink Partners | $30.00 | $17.27 | 73.71% | 169.54% |
| Aug 17, 2022 | - | Piper Sandler | $43.00 | $20.62 | 108.54% | 286.34% |
| Aug 05, 2022 | - | Leerink Partners | $37.00 | $20.37 | 81.64% | 232.43% |
| May 20, 2022 | - | Leerink Partners | $48.00 | $14.38 | 233.80% | 331.27% |
The latest Replimune Group stock forecast, released on Jun 07, 2024 by Robert Burns from H.C. Wainwright, set a price target of $17.00, which represents a 139.10% increase from the stock price at the time of the forecast ($7.11), and a 52.74% increase from REPL last price ($11.13).
Replimune Group Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $14.67 |
| Last Closing Price | $11.13 | $11.13 | $11.13 |
| Upside/Downside | -100.00% | -100.00% | 31.81% |
In the current month, the average price target of Replimune Group stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Replimune Group's last price of $11.13. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 08, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Jun 07, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jun 07, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 04, 2024 | Barclays | Overweight | Overweight | Hold |
| May 17, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Dec 06, 2023 | Barclays | Overweight | Overweight | Hold |
| Dec 12, 2022 | BMO Capital | Outperform | Outperform | Hold |
| Dec 07, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Replimune Group's last stock rating was published by BMO Capital on Sep 10, 2024. The company gave REPL a "Outperform" rating, the same as its previous rate.
Replimune Group Financial Forecast
Replimune Group Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $141.43M | $133.92M | $124.84M | $115.80M | $110.35M | $102.23M | $93.19M | $85.42M | $78.66M | $71.22M | $63.49M | $22.80M | $9.28M | $5.58M | $3.48M | $742.86K | - | - | - |
| High Forecast | $141.43M | $133.92M | $124.84M | $115.80M | $110.35M | $102.23M | $93.19M | $85.42M | $78.66M | $71.22M | $63.49M | $22.80M | $9.28M | $5.58M | $3.48M | $742.86K | - | - | - |
| Low Forecast | $141.43M | $133.92M | $124.84M | $115.80M | $110.35M | $102.23M | $93.19M | $85.42M | $78.66M | $71.22M | $63.49M | $22.80M | $9.28M | $5.58M | $3.48M | $742.86K | - | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Replimune Group's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. REPL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Replimune Group EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict REPL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Replimune Group's previous annual EBITDA (undefined) of $NaN.
Replimune Group Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $7.01M | $3.83M | $-159.13K | $-4.30M | $-6.54M | $-10.20M | $-14.36M | $-17.84M | $-20.80M | $-24.12M | $-27.76M | $-46.87M | $-54.83M | $-59.33M | $-59.67M | $-55.58M | $-56.35M | $-57.35M | $-59.29M |
| High Forecast | $7.01M | $3.83M | $-159.13K | $-4.30M | $-6.54M | $-10.20M | $-14.36M | $-17.84M | $-20.80M | $-24.12M | $-27.76M | $-46.87M | $-54.83M | $-59.33M | $-59.67M | $-55.58M | $-56.35M | $-51.39M | $-59.29M |
| Low Forecast | $7.01M | $3.83M | $-159.13K | $-4.30M | $-6.54M | $-10.20M | $-14.36M | $-17.84M | $-20.80M | $-24.12M | $-27.76M | $-46.87M | $-54.83M | $-59.33M | $-59.67M | $-55.58M | $-56.35M | $-64.80M | $-59.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Replimune Group's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. REPL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Replimune Group SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Replimune Group's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to REPL last annual SG&A of $NaN (undefined).
Replimune Group EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $0.10 | $0.06 | $-0.00 | $-0.06 | $-0.09 | $-0.15 | $-0.21 | $-0.26 | $-0.30 | $-0.35 | $-0.40 | $-0.68 | $-0.79 | $-0.86 | $-0.86 | $-0.80 | $-0.81 | $-0.83 | $-0.86 |
| High Forecast | $0.10 | $0.06 | $-0.00 | $-0.06 | $-0.09 | $-0.15 | $-0.21 | $-0.26 | $-0.30 | $-0.35 | $-0.40 | $-0.68 | $-0.79 | $-0.86 | $-0.86 | $-0.80 | $-0.81 | $-0.74 | $-0.86 |
| Low Forecast | $0.10 | $0.06 | $-0.00 | $-0.06 | $-0.09 | $-0.15 | $-0.21 | $-0.26 | $-0.30 | $-0.35 | $-0.40 | $-0.68 | $-0.79 | $-0.86 | $-0.86 | $-0.80 | $-0.81 | $-0.94 | $-0.86 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Replimune Group's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to REPL previous annual EPS of $NaN (undefined).
Replimune Group Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| PRTC | PureTech Health | $19.62 | $57.00 | 190.52% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| NAMS | NewAmsterdam Pharma Company | $15.96 | $36.00 | 125.56% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
REPL Forecast FAQ
Is Replimune Group a good buy?
Yes, according to 6 Wall Street analysts, Replimune Group (REPL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of REPL's total ratings.
What is REPL's price target?
Replimune Group (REPL) average price target is $24.2 with a range of $13 to $43, implying a 117.43% from its last price of $11.13. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Replimune Group stock go up soon?
According to Wall Street analysts' prediction for REPL stock, the company can go up by 117.43% (from the last price of $11.13 to the average price target of $24.2), up by 286.34% based on the highest stock price target, and up by 16.80% based on the lowest stock price target.
Can Replimune Group stock reach $20?
REPL's average twelve months analyst stock price target of $24.2 supports the claim that Replimune Group can reach $20 in the near future.
What are Replimune Group's analysts' financial forecasts?
Replimune Group's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $298.78M (high $298.78M, low $298.78M), average EBITDA is $0 (high $0, low $0), average net income is $-90.53M (high $-90.53M, low $-90.53M), average SG&A $0 (high $0, low $0), and average EPS is $-1.308 (high $-1.308, low $-1.308). REPL's analysts financial forecasts for the fiscal year (Mar 2028) are as follows: average revenue is $421.57M (high $421.57M, low $421.57M), average EBITDA is $0 (high $0, low $0), average net income is $-35.389M (high $-35.389M, low $-35.389M), average SG&A $0 (high $0, low $0), and average EPS is $-0.512 (high $-0.512, low $-0.512).